Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Priya Bhosale

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4014-4941; OpenAlex author ID A5082283107. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 8 papers · 2019: 2 papers · 2020: 5 papers · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper

Papers 32

  1. Imaging for Early Detection of Pancreatic Ductal Adenocarcinoma: Updates and Challenges in the Implementation of Screening and Surveillance Programs. Co-author DOI 10.2214/ajr.24.31151↗
  2. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  3. Radiomics analysis with three-dimensional and two-dimensional segmentation to predict survival outcomes in pancreatic cancer. Last author DOI 10.4329/wjr.v15.i11.304↗
  4. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  5. Baseline CT-based Radiomic Features Aid Prediction of Nodal Positivity after Neoadjuvant Therapy in Pancreatic Cancer. Last author DOI 10.1148/rycan.210068↗
  6. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. Co-author DOI 10.1186/s12885-021-09095-7↗
  7. CT features predictive of nodal positivity at surgery in pancreatic cancer patients following neoadjuvant therapy in the setting of dual energy CT. Co-author DOI 10.1007/s00261-020-02917-5↗
  8. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  9. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  10. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC … Co-author DOI 10.1007/s00261-019-02289-5↗
  11. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, upda… Co-author DOI 10.1007/s00261-019-02290-y↗
  12. Pancreatitis and PDAC: association and differentiation. Last author DOI 10.1007/s00261-019-02292-w↗
  13. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional im… Co-author DOI 10.1007/s00261-020-02723-z↗
  14. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Co-author DOI 10.3390/cancers12123656↗
  15. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  16. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
  17. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  18. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma. Last author DOI 10.1007/s00261-017-1316-z↗
  19. Genetics of pancreatic cancer and implications for therapy. Co-author DOI 10.1007/s00261-017-1394-y↗
  20. Imaging findings of recurrent pancreatic cancer following resection. Co-author DOI 10.1007/s00261-017-1397-8↗
  21. Multi-institutional survey on imaging practice patterns in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-017-1433-8↗
  22. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  23. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic… Co-author DOI 10.1186/s13045-018-0616-2↗
  24. A Diagnostic Challenge: Pancreatic Cancer or Autoimmune Pancreatitis? Co-author DOI 10.12865/chsj.44.02.15↗
  25. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  26. The endoscopist's role in the diagnosis and management of pancreatic cancer. Co-author DOI 10.1080/17474124.2016.1176910↗
  27. Quantitative and Qualitative Comparison of Single-Source Dual-Energy Computed Tomography and 120-kVp Computed Tomography for the Assessment of Pancreatic Ducta… Co-author DOI 10.1097/rct.0000000000000295↗
  28. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Co-author DOI 10.1088/1478-3975/11/6/065002↗
  29. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Co-author DOI 10.1172/jci73455↗
  30. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Co-author DOI 10.1002/cncr.27636↗
  31. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Co-author DOI 10.1007/s11605-011-1748-7↗
  32. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Co-author DOI 10.1016/j.rcl.2012.03.008↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric Peter Tamm · 24 shared papers, 2012–2023 · strength 2.04
  2. Matthew H. G. Katz · 19 shared papers, 2012–2022 · strength 1.49
  3. Eugene Jon Koay · 15 shared papers, 2014–2022 · strength 1.23
  4. Gauri Rajani Varadhachary · 15 shared papers, 2012–2022 · strength 1.05
  5. Robert A. Wolff · 15 shared papers, 2012–2022 · strength 1.04
  6. Ott Le · 8 shared papers, 2015–2024 · strength 0.89
  7. Huamin Wang · 13 shared papers, 2012–2022 · strength 0.82
  8. Jeffrey E. Lee · 12 shared papers, 2012–2022 · strength 0.73
  9. Anirban Maitra · 9 shared papers, 2014–2022 · strength 0.67
  10. Erik V. Soloff · 6 shared papers, 2018–2024 · strength 0.67
  11. Avinash R. Kambadakone · 6 shared papers, 2018–2024 · strength 0.67
  12. Sanaz Javadi · 5 shared papers, 2018–2022 · strength 0.63
  13. Milind M. Javle · 9 shared papers, 2014–2022 · strength 0.60
  14. Jason B. Fleming · 11 shared papers, 2012–2020 · strength 0.56
  15. Sherif B. Elsherif · 3 shared papers, 2020–2023 · strength 0.50
  16. Naveen M. Kulkarni · 4 shared papers, 2020–2024 · strength 0.50
  17. Elizabeth M. Hecht · 4 shared papers, 2020–2024 · strength 0.50
  18. Mohamed Zaid · 6 shared papers, 2018–2022 · strength 0.48
  19. Christopher H. Crane · 9 shared papers, 2012–2022 · strength 0.44
  20. Michael P. Kim · 5 shared papers, 2017–2022 · strength 0.42
  21. Zhen J. Wang · 4 shared papers, 2020–2023 · strength 0.41
  22. Marc Zins · 4 shared papers, 2020–2023 · strength 0.41
  23. Laura R. Prakash · 5 shared papers, 2017–2021 · strength 0.40
  24. Ajit Harishkumar Goenka · 3 shared papers, 2020–2024 · strength 0.40
  25. Michael James Overman · 5 shared papers, 2017–2022 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.